United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 20 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets usp are indicated to: - reduce the risk of myocardial infarction (mi). - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. pravastatin sodium tablets usp are indicated: - as an adjunct to diet to reduce elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apob), and triglyceride (tg) levels and to increase high-density lipoprotein chol

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 40 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets usp are indicated to: - reduce the risk of myocardial infarction (mi). - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. pravastatin sodium tablets usp are indicated: - as an adjunct to diet to reduce elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apob), and triglyceride (tg) levels and to increase high-density lipoprotein chol

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pravastatin sodium - tablet - 10 milligram(s) - hmg coa reductase inhibitors; pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pravastatin sodium - tablet - 40 milligram(s) - hmg coa reductase inhibitors; pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pravastatin sodium - tablet - 20 milligram(s) - hmg coa reductase inhibitors; pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - pravastatin sodium - tablets - 10 milligram - pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - pravastatin sodium - tablets - 40 milligram - pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

apotex europe limited - pravastatin sodium - tablets - 10 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

apotex europe limited - pravastatin sodium - tablets - 40 milligram